CN113950334B - 乙型肝炎病毒特异性t细胞应答 - Google Patents

乙型肝炎病毒特异性t细胞应答 Download PDF

Info

Publication number
CN113950334B
CN113950334B CN202080042152.1A CN202080042152A CN113950334B CN 113950334 B CN113950334 B CN 113950334B CN 202080042152 A CN202080042152 A CN 202080042152A CN 113950334 B CN113950334 B CN 113950334B
Authority
CN
China
Prior art keywords
hbv
mhc
antigen
cells
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080042152.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113950334A (zh
Inventor
克劳斯·J·弗吕
路易斯·J·皮克
本杰明·J·布尔维茨
斯克特·G·汉森
约拿·B·萨夏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of CN113950334A publication Critical patent/CN113950334A/zh
Application granted granted Critical
Publication of CN113950334B publication Critical patent/CN113950334B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080042152.1A 2019-06-07 2020-06-05 乙型肝炎病毒特异性t细胞应答 Active CN113950334B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858764P 2019-06-07 2019-06-07
US62/858,764 2019-06-07
PCT/US2020/036480 WO2020247858A1 (en) 2019-06-07 2020-06-05 Hepatitis b virus-specific t cell responses

Publications (2)

Publication Number Publication Date
CN113950334A CN113950334A (zh) 2022-01-18
CN113950334B true CN113950334B (zh) 2025-01-28

Family

ID=73653370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042152.1A Active CN113950334B (zh) 2019-06-07 2020-06-05 乙型肝炎病毒特异性t细胞应答

Country Status (5)

Country Link
US (1) US12599658B2 (https=)
EP (1) EP3980061A4 (https=)
JP (2) JP2022535458A (https=)
CN (1) CN113950334B (https=)
WO (1) WO2020247858A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980061A4 (en) 2019-06-07 2023-07-19 Oregon Health & Science University HEPATITIS B VIRUS SPECIFIC T LYMPHOCYTE RESPONSES
MX2022002270A (es) * 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6417324B1 (en) 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US20020069244A1 (en) 1999-11-24 2002-06-06 John Blair Message delivery system billing method and apparatus
US20140014103A1 (en) 2012-07-12 2014-01-16 The Research Foundation Of State University Of New York Methods, Devices and Formulations for Targeted Endobronchial Therapy
WO2008039148A1 (en) 2006-09-28 2008-04-03 Packetfront Sweden Ab Method for automatically providing a customer equipment with the correct service
TWI403247B (zh) 2008-07-18 2013-07-21 Delta Electronics Inc 具把手結構之抽取式電子裝置
JP2013112651A (ja) 2011-11-29 2013-06-10 Niigata Beer Co Ltd トリュフ抽出物を含有したｄｈｅａ産生促進剤及びその用途
FR2993576B1 (fr) 2012-07-20 2018-05-18 Nanoplas Dispositif de traitement d'un objet par plasma
US9603790B2 (en) 2012-11-15 2017-03-28 Basf Corporation Cosmetic compositions comprising marine plants
WO2014135209A1 (en) 2013-03-06 2014-09-12 SiEVA Apparatus for high side transistor bridge driver
US10532099B2 (en) 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
EP3980061A4 (en) 2019-06-07 2023-07-19 Oregon Health & Science University HEPATITIS B VIRUS SPECIFIC T LYMPHOCYTE RESPONSES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice;Yuxia Zhang等;Immunology;第121卷(第1期);摘要、第108页右栏第2段至第109页左栏第1段、图4 *

Also Published As

Publication number Publication date
WO2020247858A1 (en) 2020-12-10
US12599658B2 (en) 2026-04-14
JP2025118754A (ja) 2025-08-13
EP3980061A4 (en) 2023-07-19
EP3980061A1 (en) 2022-04-13
JP2022535458A (ja) 2022-08-08
US20220257748A1 (en) 2022-08-18
CN113950334A (zh) 2022-01-18

Similar Documents

Publication Publication Date Title
US11305015B2 (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
JP6816031B2 (ja) 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
US20200368333A1 (en) Cmv vectors comprising microrna recognition elements
JP2025118754A (ja) Ｂ型肝炎ウイルス特異的なｔ細胞応答
US20240384296A1 (en) Recombinant hcmv vectors and uses thereof
JP2022544704A (ja) ヒトサイトメガロウイルスのｕｌ１８によるｔ細胞応答の調節
EA046730B1 (ru) Модуляция т-клеточных ответов посредством ul18 цитомегаловируса человека
HK40011160A (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
HK1260171A1 (en) Cmv vectors comprising microrna recognition elements

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant